This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Bitterman DS , Winter KA , Hong TS , Fuchs CS , Regine WF , Abrams RA , Safran H , Hoffman JP , Benson AB 3rd , Kasunic T , Mulcahy M , Strauss JF , DiPetrillo T , Stella PJ , Chen Y , Plastaras JP , Crane CH
Impact of diabetes and insulin use on prognosis in patients with resected pancreatic cancer: an ancillary analysis of NRG Oncology RTOG 9704
Int J Radiat Oncol Biol Phys. 2021 Jan;109(1) :201-211
PMID: 32858111 PMCID: PMC7736166 URL: https://www.ncbi.nlm.nih.gov/pubmed/32858111
AbstractPURPOSE: Diabetes mellitus (DM) has been proposed to be tumorigenic however, prior studies of the association between DM and survival are conflicting. The goal of this ancillary analysis of XXXX, a randomized controlled trial of adjuvant chemotherapy in pancreatic cancer, was to determine the prognostic impact of DM and insulin use on survival. PATIENTS AND METHODS: Eligible patients from XXXX with available data on DM and insulin use were included. Overall survival (OS) and disease-free survival (DFS) were estimated by Kaplan-Meier method and variable levels were compared using log-rank test. Cox proportional hazards models were created to assess the association between DM, insulin use, and body mass index (BMI) phenotypes on outcomes. RESULTS: Of 538 patients enrolled from 1998-2002, 238 patients were eligible with analyzable DM and insulin use data. Overall 34% of patients had DM and 66% did not. Of patients with DM, 64% had insulin dependent DM, and 36% had non-insulin dependent DM. On univariable analysis, neither DM nor insulin dependence were associated with OS or DFS (P>0.05 for all). On multivariable analysis, neither DM, insulin use, nor BMI were independently associated with OS or DFS. Non-white race (HR 2.18, 95% confidence interval (CI) 1.35-3.50, P=0.0014), nodal involvement (HR 1.74, 95% CI 1.24-2.45, P=0.0015), and carbohydrate antigen 19-9 (CA19-9) ≥ 90 U/mL (HR 3.61, 95% CI 2.32-5.63, P<0.001) were associated with decreased OS. Non-white race (HR 1.67, 95% CI 1.05-2.63, P=0.029) and CA19-9 ≥ 90 U/mL (HR 2.86, 95% CI 1.85-4.40, P<0.001) were associated with decreased DFS. CONCLUSIONS: DM and insulin use were not associated with OS or DFS in patients with pancreatic cancer in this study. Race, nodal involvement, and increased CA19-9 were significant predictors of outcomes. These data may or may not apply to the more modern use of neoadjuvant therapies for potentially resectable pancreatic cancer.
Notes1879-355x Bitterman, Danielle S Winter, Kathryn A Hong, Theodore S Fuchs, Charles S Regine, William F Abrams, Ross A Safran, Howard Hoffman, John P Benson, Al B 3rd Kasunic, Timothy Mulcahy, Mary Strauss, James F DiPetrillo, Thomas Stella, Philip J Chen, Yuhchyau Plastaras, John P Crane, Christopher H Journal Article United States Int J Radiat Oncol Biol Phys. 2020 Aug 25:S0360-3016(20)34137-7. doi: 10.1016/j.ijrobp.2020.08.042.